March 15, 2018 04:43 AM EDTUpdated 02:53 PM

The biotech IPO party rocks on with $120M raise for I/O player Arcus Biosciences

John Carroll

Editor & Founder

Arcus Biosciences provided fresh evidence that the biotech IPO window is open for business — particularly if you have a claim to future immuno-oncology glory. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The biotech IPO party rocks on with $120M raise for I/O player Arcus Biosciences

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test

The biotech IPO par­ty rocks on with $120M raise for I/O play­er Ar­cus Bio­sciences

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

The biotech IPO party rocks on with $120M raise for I/O player Arcus Biosciences

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

Outlook's shares crash as wet AMD drug flunks Phase 3 test